The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...
The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback